82.07

2.04% -1.71

Ani Pharmaceuticals Inc (ANIP)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Ani Pharmaceuticals Inc stock is traded at $82.07, with a volume of 241.43K. It is down -2.04% in the last 24 hours and up +0.27% over the past month. ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Previous Close:

$83.78

Open:

$84.02

24h Volume:

241.43K

Relative Volume:

0.69

Market Cap:

$1.87B

Revenue:

$923.71M

Net Income/Loss:

$84.68M

P/E Ratio:

20.82

EPS:

3.9419

Net Cash Flow:

$182.81M

1W Performance:

-4.60%

1M Performance:

+0.27%

6M Performance:

+7.59%

1Y Performance:

+24.16%

1-Day Range:

$81.97

$85.90

1-Week Range:

$81.97

$87.19

52-Week Range:

$62.60

$99.50

Ani Pharmaceuticals Inc Stock (ANIP) Company Profile

Name

Ani Pharmaceuticals Inc

Sector

Healthcare (1096)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

(609) 759-1810

Address

104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN

Employee

970

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

ANIP's Discussions on Twitter

Compare ANIP vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANIP Ani Pharmaceuticals Inc	82.07	1.87B	923.71M	84.68M	182.81M	3.9419
TAK Takeda Pharmaceutical Co Adr	16.56	52.88B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.76	42.98B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	32.95	38.37B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.56	31.68B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.06	23.22B	3.17B	1.29B	1.01B	27.09

Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-10-25	Initiated	H.C. Wainwright	Buy
Mar-14-25	Initiated	Jefferies	Buy
Mar-12-25	Initiated	JP Morgan	Overweight
Dec-11-24	Initiated	Leerink Partners	Outperform
Oct-11-24	Initiated	Piper Sandler	Overweight
Mar-15-24	Initiated	CapitalOne	Overweight
Aug-22-23	Reiterated	H.C. Wainwright	Buy
Mar-01-23	Initiated	Guggenheim	Buy
Sep-07-22	Initiated	H.C. Wainwright	Buy
Nov-02-21	Initiated	Truist	Buy
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform
Oct-16-17	Reiterated	Canaccord Genuity	Buy
Jul-31-17	Initiated	Canaccord Genuity	Buy
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy
Aug-05-15	Reiterated	Oppenheimer	Outperform
Aug-04-15	Reiterated	ROTH Capital	Neutral
Jul-31-15	Reiterated	Oppenheimer	Outperform
Jul-15-15	Reiterated	ROTH Capital	Neutral
Jun-23-15	Reiterated	Oppenheimer	Outperform
May-18-15	Reiterated	ROTH Capital	Neutral
May-06-15	Reiterated	Oppenheimer	Outperform
Apr-10-15	Downgrade	ROTH Capital	Buy → Neutral
Feb-26-15	Reiterated	ROTH Capital	Buy
Feb-18-15	Reiterated	Oppenheimer	Outperform

View All

Ani Pharmaceuticals Inc Stock (ANIP) Latest News

Jul 11, 2026

ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity? - Sahm

Jul 11, 2026

Jul 09, 2026

ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge - Yahoo Finance

Jul 09, 2026

Enterprise value to revenue forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP - TradingView

Jul 09, 2026

Jul 07, 2026

Price to sales forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP - TradingView

Jul 07, 2026

Form 144 ANI Pharmaceuticals For: 7 July By Investing.com - Investing.com India

Jul 07, 2026

ANIP (ANIP) insider sales reported: Walsh sold 13,973 shares in May 2026 - Stock Titan

Jul 07, 2026

Is Stronger Free Cash Flow Signalling a Shift in ANI Pharmaceuticals' Capital Efficiency Story (ANIP)? - Sahm

Jul 07, 2026

Ani Pharmaceuticals SVP & CFO Stephen Carey sells $284k in stock - Investing.com Australia

Jul 07, 2026

Jul 06, 2026

Form 4 ANI Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026

ANI Pharmaceuticals (ANIP) CFO sells 3,313 shares after option exercise - Stock Titan

Jul 06, 2026

Price to earnings forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP - TradingView

Jul 06, 2026

Jul 05, 2026

ANI Pharmaceuticals set to report earnings amid estimate cuts - Investing.com

Jul 05, 2026

Jun 30, 2026

Insider Sell: Stephen Carey Sells Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus

Jun 30, 2026

ANI Pharmaceuticals (ANIP) CFO Stephen Carey sells 2,850 shares under Rule 10b5-1 plan - Stock Titan

Jun 30, 2026

Jun 26, 2026

ANI Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ANIP) - TradingView

Jun 26, 2026

ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple (NASDAQ:ANIP) - Seeking Alpha

Jun 26, 2026

ANIP Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 25, 2026

ANI Pharmaceuticals, Inc. Actuals & Estimates (BOATS:ANIP) - TradingView

Jun 25, 2026

Jun 21, 2026

ANI Pharmaceuticals (ANIP) Stock Could Be 29.5% Below Fair Value After Recent Pullback - Sahm

Jun 21, 2026

Jun 20, 2026

ANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $114.17, Implies 44% Upside - TradingView

Jun 20, 2026

Jun 17, 2026